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Adenine-induced hyperphosphatemia in a murine model of renal
insufficiency
Abstract
Hyperphosphatemia in chronic kidney disease (CKD) patients is a risk factor for cardiovascular events,
progressive kidney failure, and mortality. Improved therapeutic interventions to control hyperphosphatemia
depend greatly on robust animal models that recapitulate the CKD disease process. Murine-based models of
CKD as compared to rat models present significant advantages due to available genetic knockout lines that
permit mechanistic dissection of CKD etiologies. The rat adenine model of renal failure has been extensively
studied, and studies are now emerging describing adenine-induced renal failure in murine models. However,
these newly developed murine models have not fully described the responses to calcitriol and phosphate
binders, and the reported effects of adenine on serum phosphate is often lacking in murine models. Therefore,
the objectives of this study were: 1) To induce hyperphosphatemia in mice using adenine with minimal
mortality, and 2) Report the influence of calcitriol and phosphate binders on the disease process through
measurement of serum phosphate and histology. In one approach, C57BL/6 male mice gavaged with 4 or 6
mg adenine/day, as compared to 0 mg adenine/day developed hyperphosphatemia, with low mortality. In a
second approach, calcitriol exacerbated adenine-induced increases in serum phosphate at day 7 of adenine
administration (p<0.05). Notably, adenine treated mice had 4-fold increased stomach weights vs. non-
adenine treated mice (p<0.0001). The addition of a phosphate binder (experiment 3, sevelamer
hydrochloride) was ineffective at preventing an adenine-induced increase in blood phosphate, a finding that
likely resulted from adenine’s inhibition of gastric emptying. We report the successful use of adenine to induce
hyperphosphatemia, that the hyperphosphatemic status is exacerbated by calcitriol, and a limitation of the
model for studying oral therapies for hyperphosphatemia.
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Abstract
Hyperphosphatemia in chronic kidney disease (CKD) patients is a risk factor for cardiovascular events, progressive kidney failure, and mortality. Improved therapeutic 
interventions to control hyperphosphatemia depend greatly on robust animal models that recapitulate the CKD disease process. Murine-based models of CKD as 
compared to rat models present significant advantages due to available genetic knockout lines that permit mechanistic dissection of CKD etiologies. The rat adenine 
model of renal failure has been extensively studied, and studies are now emerging describing adenine-induced renal failure in murine models. However, these 
newly developed murine models have not fully described the responses to calcitriol and phosphate binders, and the reported effects of adenine on serum phosphate 
is often lacking in murine models. Therefore, the objectives of this study were: 1) To induce hyperphosphatemia in mice using adenine with minimal mortality, 
and 2) Report the influence of calcitriol and phosphate binders on the disease process through measurement of serum phosphate and histology. In one approach, 
C57BL/6 male mice gavaged with 4 or 6 mg adenine/day, as compared to 0 mg adenine/day developed hyperphosphatemia, with low mortality. In a second 
approach, calcitriol exacerbated adenine-induced increases in serum phosphate at day 7 of adenine administration (p<0.05). Notably, adenine treated mice had 4-fold 
increased stomach weights vs. non-adenine treated mice (p<0.0001). The addition of a phosphate binder (experiment 3, sevelamer hydrochloride) was ineffective at 
preventing an adenine-induced increase in blood phosphate, a finding that likely resulted from adenine’s inhibition of gastric emptying. We report the successful use 
of adenine to induce hyperphosphatemia, that the hyperphosphatemic status is exacerbated by calcitriol, and a limitation of the model for studying oral therapies for 
hyperphosphatemia.
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Introduction 
Hyperphosphatemia, a sequelae of chronic kidney disease (CKD), 
is responsible for decreased survival due to coronary artery disease, 
among other complications [1,2]. High blood phosphate levels in CKD 
patients are controlled by consuming diets low in inorganic phosphate, 
prescription of oral phosphate binders to bind dietary inorganic 
phosphate, and in the case of end stage failure, dialysis [3]. Improved 
methods to treat hyperphosphatemia are needed, as recent work 
capturing patient compliance reported that up to 45% of patients do 
not follow prescribed guidelines for use of oral phosphate binders [4,5]. 
Furthermore, concurrent active vitamin D supplementation prescribed 
due to a reduced ability of the kidney to convert vitamin precursors 
to active vitamin D further exacerbates phosphate absorption [6,7]. 
Previously, the rat models including the 5/6 nephrectomy and adenine-
induced kidney insufficiency rat model have been extensively used for 
pre-clinical testing in the development of therapies for chronic kidney 
disease [8-10]. The rat adenine-induced kidney insufficiency model 
is a less invasive refinement over the 5/6 nephrectomy surgical renal 
insufficiency model [11,12], and was found useful in the development 
of sevelamer hydrochloride (Sev HCl) as an oral therapy for treatment 
of hyperphosphatemia [10]. Rats fed 0.75% dietary adenine for two 
weeks developed increased blood phosphate, FGF23, and blood urea 
nitrogen due to renal insufficiency, appearing sufficient to model 
human CKD [8,9,11]. 
Only recently have murine models of CKD employed the use 
of adenine; a desirable extension of the rat model due to ease of 
genetic manipulation and conservation of testable compounds [2,13-
16]. Male C57BL/6 mice supplemented with 0.25% adenine had an 
accumulation of collagen and 2,8-dihydroxyadenine in renal tubules 
and an accompanying macrophage infiltrate [13]. Adenine-induced 
histological changes and select blood parameters in male C57BL/6 
mice fed 0.75% adenine has also been described [14], and reported 
that 0.75% adenine was lethal by day 6. Neither report evaluated the 
effects on blood phosphate status, a hallmark of human CKD. In a 
separate report, authors found that C57BL/6J mice fed 2% adenine in a 
casein-based diet had inconsistently increased serum phosphate over a 
d10-60 exposure period [15]. In a preliminary study in our laboratory, 
C57BL/6 male mice fed 0.25% or higher adenine showed outright food 
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refusal within 3 days (3 g/day to <1 g/day, unpublished data). Previous 
reports using 0.20% dietary adenine did not report anorexia but did 
show significant weight loss by day 10 of feeding adenine compared 
to control mice [15]. Exposure to adenine through food may have 
secondary anorexia effects through food refusal and may confound 
the examination of diet-based therapies, hence gavage was selected to 
ensure a daily dose of adenine regardless of feed intake.
Therefore, the objectives of this study were to: 1) Find a gavage dose 
of adenine that induced hyperphosphatemia without causing mortality; 
2) Test the influence of calcitriol (a common active vitamin D therapy 
for CKD patients, and also known to increase phosphate absorption) 
in the mouse adenine model; and 3) Determine if sevelamer HCl, a 
phosphate binder, prevents hyperphosphatemia in the mouse adenine 
model. Here, we report successful induction of hyperphosphatemia 
that was exacerbated by calcitriol supplementation. We also found that 
adenine interferes with gastric emptying; a limitation of this model in 
the study of oral therapies for preventing hyperphosphatemia.
Materials and methods
Experiment 1
All animal experimental procedures were approved by the 
University of Wisconsin-Madison College of Agricultural and Life 
Sciences Animal Care and Use Committee. Animals were housed in 
a facility with accreditation from AAALAC for the duration of the 
experiment. Adult male C57BL/6 7-8 weeks of age with littermate 
identity (Harlan Teklad, Madison, WI, n=36, 12 per treatment) were 
housed 3 per shoebox cage, as littermates, with a 12 h light/dark cycle. 
Mice were allowed free access to distilled water and a semi-purified 
sucrose/casein based diet (TD.10050, Harlan-Teklad, Madison, WI) 
formulated based on the AIN-76A diet (TD.94060, Harlan-Teklad) 
during a 7-day acclimatization period. This diet contained 6.85 g 
calcium/kg diet and 5.61 g phosphate/kg diet, with a calcium:phosphate 
ratio of 1.22. Following acclimatization, 12 mice (4 cages of 3 mice) were 
assigned to each of the following gavage treatments where gavage was 
accomplished once daily for 14 days using an 18-gauge curved feeding 
needle: 1:200 μl ddH2O oral gavage; 2:4 mg adenine (99.8% pure, 
Calbiochem, La Jolla, CA) in 200 μl ddH2O; or 3:6 mg adenine in 200 μl 
ddH2O. As mice were expected to lose weight and body condition due 
to adenine treatment during induction of renal insufficiency, mice were 
removed from the experiment if they were observed to not eat or drink, 
or when body weight loss was >40%. Mice were weighed weekly and 
then bled under light isoflurane anesthesia using the axillary bleeding 
method at day 7 or 14 of the experimental gavaging period (6 mice were 
euthanized per time point). Euthanasia after bleeding under anesthesia 
was performed by cervical dislocation. Blood was collected into 400µl 
serum separator tubes (BD Medical, Franklin Lakes, NJ) and serum 
was separated and stored at -80°C until phosphate, urea, and FGF23 
were analyzed. The right kidney of each mouse was weighed separately 
for determination of kidney weight as a percentage of bodyweight. 
Serum analysis
To determine serum phosphate, samples were analyzed in a 96-well 
Nunc Immunosorp flat-bottomed plate (Fisher Scientific, Rockford, Il) 
using the Pointe Scientific inorganic phosphorus reagent set (Canton, 
MI, P7516) and inorganic phosphorus standard (P7516-STD). Samples 
were loaded onto 2 duplicate plates; one for phosphorus reagent and 
the second was blanked using saline (control for each sample). Plates 
were read using a SpectraMax190 Plate reader (Molecular Devices, 
Sunnyvale, CA) with the SoftMax Pro 4.7.1 analysis program (Molecular 
Devices, Sunnyvale, CA). Blanked values (phosphorus reagent-blank) 
were used to calculate final OD’s to reduce overestimation of serum 
phosphate in the event of red blood cell lysis. Hence, the presence of 
lysis was indicated in results in Experiment 1. 
Urea was analyzed in a 96-well plate using mouse serum and 
BioAssay Systems Quantichrom Urea Assay Kit according to 
manufacturer’s instructions (DIUR-500, Hayward, CA). Remaining 
samples were analyzed using the Mouse FGF23 C-terminal ELISA 
kit (Immutopics International, San Clemente, CA) according to 
manufacturer directions. Control samples (no adenine) were not 
diluted for the FGF23 analysis; however, serum from adenine-treated 
animals was diluted 1:10 using C-term sample diluent (Immutopics 
International, San Clemente, CA) in order to assure samples were 
within the standard curve. 
Experiment 2
Adult male C57BL/6 7-8 weeks of age with littermate identity 
(Harlan Teklad, n=72, 18 per treatment) were housed 3 per cage with 
a 12 h light/dark cycle and fed a semi-purified sucrose/casein-based 
diet based on AIN76-A (Harlan Teklad TD.110109). Following a 7-day 
acclimatization period, mice were assigned to one of 4 daily gavage 
treatments in order to determine the interaction of calcitriol (active 
Vitamin D) and renal failure, and resulting phosphate status: 1) 200 
cμl corn oil; 2) 200 cμl corn oil supplying 0.5 ug/kg body weight/day 
calcitriol (Enzo Life Sciences, Farmingdale, NY); 3) 200 μl corn oil 
containing a suspension of 4 mg adenine; 4) 200 μl corn oil supplying 
0.5 ug/kg bodyweight/day calcitriol plus 4 mg adenine. Corn oil was 
used as a vehicle to accommodate calcitriol. Adenine dose (4 mg/
day) was selected based on results from experiment 1, which was the 
lowest dose of adenine that led to kidney dysfunction as measured by 
increased kidney weight, plasma urea, FGF23, and serum phosphate. 
Animals were gavaged for 14 days, weighed weekly, monitored, 
and bled as described in experiment 1. Additionally, stomachs were 
collected, weighed, and expressed as percentage of bodyweight.
Experiment 3
Adult male C57BL/6 7-8 weeks of age with littermate identity 
(Harlan Teklad, n=48, 12 per treatment) were housed 3 per cage with a 
12 h light/dark cycle. Mice were fed the diet as described in experiment 
1 with or without a phosphate binder (1% sevelamer HCl, Genzyme 
Corporation, Cambridge, MA; replacing a cellulose filler in the diet) 
and with or without daily adenine gavage (0 or 4 mg/day in 200 μl 
ddH2O, as described above) to provide the following treatment groups; 
1) Control diet with 0 mg adenine gavage; 2) 1% dietary sevelamer HCl 
with 0 mg adenine gavage; 3) Control diet with 4 mg adenine gavage; or 
4) 1% dietary sevelamer HCl with 4 mg adenine gavage. Concentration 
of sevelamer was based on previous experiments in chick diets where 
1% was successful in reducing plasma phosphate and bone ash [17], as 
well as the calculation that 1 g sevelamer can bind 0.45 g phosphate, 
hence 1% sevelamer could bind up to 80% of the phosphate in the 
mouse diet (which contains 0.56% phosphate [18]). The remaining 
0.13% phosphate in the diet would leave the mice severely deficient. 
Diets were fed for 2 weeks and mice were bled, organs were collected, 
and serum was analyzed as described above. 
Kidney histology
Upon sacrifice, kidneys were weighed and then transferred into 
10% buffered formalin (Fisher Scientific, Waltham, MA) for 24-hour 
fixation at room temperature. Individual kidneys were embedded in 
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paraffin, sectioned, and stained with hematoxylin and eosin (H&E) 
before analysis by a board licensed veterinary pathologist (Author: 
DJS). Kidneys selected for photos were representative samples of 7- 
and 14-day controls, 7- and 14-day with 4 mg adenine gavage, 7- and 
14-day with 6 mg adenine gavage, and 7-and 14-day 4 mg gavage with 
calcitriol supplementation. Photos were taken at 200x on a Nikon 
Eclipse 50i Microscope (Melville, NY).
Statistical analyses
Data were analyzed using a one-way ANOVA for experiment 1, 
and a two-way ANOVA with a 2×2 factorial arrangement of treatments 
in experiments 2 and 3 (experiment 2: with or without adenine and/
or active D (calcitriol), experiment 3: with or without adenine and/or 
sevelamer HCl) (SAS Institute Inc., Cary, NC). Data in experiment 2 
were analyzed for main effects of adenine, VitD (calcitriol), and the 
adenine X VitD interaction. Data in experiment 3 were analyzed for 
adenine, sevelamer HCl, and the adenine X sevelamer HCl interaction. 
Post-ANOVA analyses comparisons of mean treatment differences 
were conducted even if the interactions were not significant (p>0.05) 
using least squared differences such that significant effects could be 
easily discerned. The p values for main effects and interactions were 
provided for discernment regarding the least square differences. Data 
were expressed as mean and the overall standard error of the mean for 
each variable was provided.
Results
Experiment 1
The goal of this experiment was to identify a minimum level of 
gavaged adenine that induced hyperphosphatemia but did not increase 
mortality. In a preliminary trial (not shown), mice were gavaged with 0, 
1, or 3 mg adenine per day. After two weeks, average serum phosphate 
of the three groups were 7.0, 6.9, and 7.6 mg/dL, respectively, hence 
higher doses of adenine (>3 mg/day) appeared necessary to effectively 
induce hyperphosphatemia. In experiment 1, gavaging 6 mg adenine 
per day for 7 days significantly increased serum phosphate by 2.1-
fold compared to 0 mg control (p<0.01); at 14 days, gavaging 4 or 6 
mg adenine per day significantly increased plasma phosphate above a 
vehicle gavaged control (p<0.01, Table 1). Gavaging adenine decreased 
weight at both 7 and 14 days versus vehicle control (p<0.001), but 
mortality remained minimal with only 1 mouse in the 4 mg and 2 
mice in the 6 mg groups requiring euthanasia before reaching their 
scheduled endpoint (day 7 or 14).
At day 7 and 14 days of treatment, 4 and 6 mg adenine/day 
increased serum FGF-23 (>193-fold, p<0.001), urea (4-fold, p<0.0001), 
and relative kidney weights (1.5-fold, p<0.0001). Adenine gavaged 
mice had reduced body weight (13% to 25%, p<0.001) when compared 
to mice not receiving adenine. Increase in adenine gavage from 4 to 6 
mg/day did not impact variables measured except for FGF-23 at day 7, 
where 6 mg treated mice had an additional increase in serum FGF-23 
compared to 4 mg treated mice.
Experiment 2
Supplemental calcitriol (active vitamin D) is known to increase 
phosphate absorption [6,7,19]. The goal of experiment 2 was to 
determine the interaction of active vitamin D and adenine on phosphate 
metabolism during renal dysfunction (Table 2). For all variables 
measured, the addition of adenine (main effect: adenine) significantly 
increased serum phosphate, FGF23, urea, stomach and kidney weights, 
while decreasing body weight. While calcitriol had no impact on 
variables measured in the absence of adenine treatment (independent of 
interactions), calcitriol in the presence of adenine-induced renal failure 
altered biomarkers of abnormal phosphate homeostasis (Adenine X D 
Interaction). Calcitriol, when combined with adenine, increased serum 
phosphate (day 7 only, 1.2-fold, p<0.05), FGF23 (>2-fold, p<0.0001), 
relative kidney weight (1.1-fold, p<0.05) and reduced body weight 
(≥8%, p<0.01) compared to the adenine supplementation without 
calcitriol. During necropsy for determining kidney weights (Figure 
1), it was observed that stomachs were enlarged; hence stomachs 
were collected and weighed (Figure 2). Apart from the enlargement 
(approximately 4-fold) due to adenine treatment (p<0.0001), calcitriol 
had no effect on stomach tissue weights (emptied and weighed). Total 
mortality, including euthanasia according to protocol and before 
endpoints, was 0 in control mice, 1 in + vitamin D mice, 3 in + adenine 
mice, and 4 in + adenine + vitamin D mice. 
Experiment 3
In experiment 3, the effectiveness of the phosphate binder, 
sevelamer HCl, to prevent adenine-induced hyperphosphatemia was 
investigated (Table 3). Sevelamer HCl was ineffective at preventing an 
adenine-induced increase in blood phosphate, urea, relative stomach 
weight and decreased body weight. On day 14, but not day 7, sevelamer 
reduced adenine induced increases in serum FGF23 (adenine X 
sevelamer, p=0.0017). Increases in kidney weight induced by adenine 
by day 14, but not day 7, was exacerbated by sevelamer treatment 
(adenine X sevelamer, p=0.04). As observed in experiment 2, adenine 
administration increased full and empty stomach weights by 3 and 1.4-
fold, respectively (p=0.0007) when compared to mice that received no 
supplemental adenine or sevelamer HCl. The addition of sevelamer 
HCl to the adenine treatment increased full and empty stomach 
Figure 1. Excised kidneys of mice from experiment 2 at day 14 either gavaged with 4mg 
adenine/ day (A) or 0mg (vehicle) (B). Mice were orally gavaged 0 or 4mg adenine for 2 
weeks and kidneys were excised for appearance and weight determination. The main effect 
of adenine on increasing kidney weight was significant at p<0.0001. Note the lighter color 
of adenine treated mice (A)
Figure 2. Excised full stomachs of mice from experiment 2 at 14 days either on control+0mg 
(vehicle) (2A) or control+4mg adenine/ day (2B). Mice were orally gavaged with 0 or 4mg 
adenine for 14 days. Stomachs of adenine-treated mice were observed to be larger during 
kidney excision; hence stomachs were collected and weighed during necropsy. The main 
effect of adenine on increasing stomach weight was significant at p<0.0001
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weights, when compared to mice only receiving adenine treatment. All 
mice in non-adenine treated groups survived until scheduled endpoint. 
One mouse was euthanized in the adenine treatment group, and two in 
the adenine+sevelamer HCl treatment group. 
Histology
Figures 3A and 3B show kidney sections of control mice at 7 and 
14 days with normal renal cortexes. At 7 and 14 days for mice receiving 
the 4 mg or 6 mg adenine gavage, kidney tubules show distention 
with dilated, degenerating epithelium and material that may represent 
crystallizing adenine metabolites consistent with previous adenine-
induced kidney injury models [20] (Figures 3C-3F). An increase in 
interstitial fibroblasts is seen in 6 mg gavage at 14 days (Figure 3F). 
Kidneys of mice gavaged for 7 or 14 days with 4 mg adenine + calcitriol 
supplementation had similar kidney injuries as mice gavaged with 4 mg 
adenine for 7 or 14 days without additional calcitriol supplementation 
(Figures 3G-3H). The effect of vitamin D toxicoses (corticomedullary 
junction mineralization) from 14 day calcitriol supplementation is 
seen in Figure 3H. In all cases of adenine gavage, crystallization is more 
evident at 14 days than at 7 days.
Discussion
Rats have been the model of choice for studying adenine-
induced hyperphosphatemia, and the advantages of murine-based 
adenine models have been recently realized and reported by several 
investigators [2,15,16,21]. A reliable model of chemically-induced 
hyperphosphatemia in mice is useful since mice require less test 
compound and knockouts are widely available for studying basic 
mechanisms involving hyperphosphatemia. It has been demonstrated 
that mice have a relatively higher sensitivity to adenine-induced 
toxicity than rats. Rats tolerate dietary levels of adenine at 0.75% for 
prolonged periods (8 weeks or more) [9,11,19,22], whereas mice show 
Treatment 
(mg/day) Pi d7 (mg/dL)
Pi d14 (mg/
dL)
FGF23 d7 (pg/
ml)
FGF23 d14 
(pg/ml)
Urea d7 (mg/
dL)
Urea d14 (mg/
dL)
Kidney d7 
(%BW)
Kidney d14 
(%BW) BW d7 (g) BW d14 (g)
Gavage 0 5.1b 11.1*b 150c 45b 90.4b 72.9b 0.73b 0.89b 23.6a 22.1b
Gavage 4 9.0ab 16.1a 28897b 13898a 352.9a 247.8a 1.21a 1.26a 18.7b 18.4c
Gavage 6 10.8a 15.9a 33821a 11347a 393.7a 267.8a 1.22a 1.33a 17.6b 19.2c
Pooled SE 1.5 0.59 5824 2408 15.2 23.4 0.05 0.08 0.57 0.49
*Lysis in 0 mg/ day gavage control group that caused artificially high serum phosphate results. 
 D: Day; Pi: Inorganic phosphate; FGF23: Ffibroblast growth factor 23; BW: Body weight
Table 1. Experiment 1. Serum measurements (phosphate, FGF23, urea) and weight (kidney and body weight) parameters of mice at day 7 and day 14 of experimental trial. Mice (n=12) 
were gavaged with either 0 (control), 4, or 6 mg adenine per day and half were euthanized at day 7 and the remainder at day 14. Results are shown above as mean with pooled standard error 
of the mean. Differing superscript letters within columns denote significant differences between treatment groups (p<0.05). 
Treatment Pi d7 (mg/dL)
Pi d14 (mg/
dL)
FGF23 d7 
(pg/ml)
FGF23 d14 
(pg/ml)
Urea d14 
(mg/dL)
Kidney d7 
(%BW)
Kidney d14 
(%BW) BW d7 (g) BW d14 (g)
Full 
Stomach d7 
(%BW)
Full 
Stomach 
d14 (%BW)
Vehicle Control 6.8c 5.8b 229c 336c 24.0b 0.76b 0.78c 24.5a 26.0a 0.69b 0.63b
VitD 5.9c 5.4b 904c 1457c 27.4b 0.78b 0.72c 24.8a 25.0a 0.65b 0.61b
Control+Adenine 10.5b 12.5a 17814b 31795b 166.4a 1.12a 1.42b 19.1b 21.1b 2.74a 2.92a
Control+Adenine+VitD 12.9a 11.5a 66535a 72270a 148.2a 1.16a 1.59a 17.5c 16.3c 2.85a 2.82a
Pooled SE 0.63 0.55 3378 1929 5.58 0.035 0.056 0.40 0.57 0.22 0.34
Main Adenine <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
Main VitD 0.253 0.216 <0.0001 <0.0001 0.204 0.462 0.29 0.103 <0.0001 0.892 0.862
Adenine x VitD 0.252 0.520 <0.0001 <0.0001 0.069 0.80 0.047 <0.001 0.002 0.752 0.898
VitD: Calcitriol; d: Day; FGF23: Fibroblast growth factor 23; BW: Bodyweight.
Post-ANOVA comparisons were made even if interactions were not significant in order to highlight main effects.
Table 2. Experiment 2. Serum, organ, and body weight results from mice gavaged 0 or 4 mg adenine/day with or without calcitriol with mean ± SEM at day 7 or 14. Mice (n=18/ group) were 
placed into one of 4 treatment groups arranged in a 2x2 factorial control diet with or without adenine (0 or 4 mg adenine/ day), and with or without calcitriol (Vit D, 0.5 μg/ kg bodyweight 
calcitriol per day) for 7 or 14 days. Kidney and stomach weights are shown as percent of bodyweight. Differing superscript letters denote significant difference between treatment group 
means within the same column (p<0.05). Main effects of VitD (calcitriol) and adenine, and the adenine X VitD interaction p values are shown
Treatment Pi d7 (mg/dL)
Pi d14 (mg/
dL)
FGF23 d7 
(pg/ml)
FGF23 d14 
(pg/ml)
Urea d14 
(mg/dL)
Kidney d7 
(%BW)
Kidney d14 
(%BW) BW d7 (g) BW d14 (g)
Full 
Stomach 
d7 (%BW)
Full 
Stomach 
d14 
(%BW)
Empty 
Stomach 
d14 
(%BW)
Control 8.4ab 7.1b 180b 302b 69.8c 0.79b 0.75c 23.4a 24.7a 0.82c 0.82c 0.39c
Sev 6.3b 8.1b 175b 234b 62.7c 0.78b 0.79c 24.5a 25.4a 0.82c 0.82c 0.54b
Control+Adenine 9.3ab 10.3b 21679a 24775a 274.7a 1.4a 1.4b 19.9b 19.6b 2.50b 3.10b 0.57b
Sev+Adenine 10.1a 10.7a 15419a 5625b 256.0b 1.4a 1.7a 18.8b 20.2b 3.50a 3.70a 0.71a
Pooled SE 1.06 0.67 3432 2593 6.2 0.04 0.05 0.64 0.45 0.22 0.19 0.05
Main Adenine 0.042 0.0004 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.001
Main Sev 0.552 0.327 0.374 0.002 0.053 0.890 0.008 0.976 0.313 0.062 0.114 <0.001
Adenine x Sev 0.176 0.666 0.375 0.002 0.353 0.97 0.040 0.089 0.942 0.062 0.229 0.924
d: Day, FGF23: Fibroblast growth factor 23, Sev: Sevelamer HCl, BW: Bodyweight.
Post-ANOVA comparisons were made even if interactions were not significant in order to highlight main effects.
Table 3. Experiment 3.  Serum, organ, and weight data (mean ± SEM) from mice (n=12/ group) placed into one of 4 treatment groups arranged in a 2x2 factorial (± adenine and ± 1% dietary 
sevelamer HCl). Mice were gavaged with 0 or 4 mg adenine/ day and received 0 or 1% dietary sevelamer HCl for 7 or 14 days. Kidney, full stomach, and empty stomach weights are shown 
as percent of bodyweight. Main effects of adenine and sevelamer, and the adenine X sevelamer interaction p values are shown. Differing superscript letters denote significant difference 
between treatment groups in the same column (p<0.05)
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Figure 3. Histology of sliced/ H&E stained kidneys from selected groups in murine adenine-induced kidney insufficiency studies. In panels A-F,C57Bl/6 mice were treated with either 0, 
4, or 6 mg adenine/ day (rows) in 200ul ddH2O for 7 or 14 days (columns). In panels G and H, mice were gavaged with 4mg adenine/ day + active vitamin D in corn oil (7 or 14 days), 
and the 0mg/ day adenine corn oil control were reflective of panels A and B. Kidneys were fixed in formalin for 24 hours at room temperature and then transferred to PBS until sectioning 
and staining with H&E.A: 7 day control, non-adenine treated control mouse. Normal renal cortex. GL, glomerulus. 200X; B: 14 day control, non-adenine treated control mouse. Normal 
renal cortex. 200X; C: 7 day 4 mg. Renal tubules are frequently distended. Some contain amorphous clear or pale brown crystals (*) and are lined by attenuated, degenerating epithelium 
(E). Brightly eosinophilic intratubular material that may represent crystallizing adenine metabolites is present at low levels (arrowhead). 200X; D: 14 day 4 mg. Renal tubules often contain 
spiky brown crystals, presumed to be adenine metabolites, as they resemble the crystals seen in the Aprt knockout mouse [20]. The crystals occasionally induce epithelial necrosis and 
subsequent suppurative inflammation (S). Tubular epithelium is often attenuated and flattened (regeneration). Crystals in various stages of nucleation are noted (*). 200X; E: 7 day 6 mg. 
Renal tubules are markedly degenerate and dilated; they are commonly lined by flattened, attenuated epithelium (E) and contain necrotic cellular debris (N) (degeneration). Eosinophilic 
material interpreted as crystallizing adenine metabolites is noted (arrowhead). 200X; F: 14 day 6 mg. Large numbers of spiky brown crystals (adenine metabolites) are noted within renal 
tubules. They appear to induce epithelial proliferation (P), thereby “coating” themselves in degenerate epithelium. Many tubules are lined by flattened, attenuated (regenerating) epithelium, 
and there is an increase in interstitial cells (fibroblasts). 200X; G: 7 day 4 mg with Vitamin D. Renal tubules are commonly filled with brightly eosinophilic debris (arrowheads); this material 
is interpreted as crystallizing adenine metabolites. Tubular epithelium is occasionally flattened or irregular (degeneration). 200X; H: 14 day 4 mg with Vitamin D. Large quantities of brightly 
eosinophilic intratubular material (arrowheads) interpreted as crystallizing adenine metabolites are noted; there is accompanying tubular degeneration. Tubules at the corticomedullary 
junction are undergoing mineralization (M), as is consistent with Vitamin D toxicosis. There are increased interstitial fibroblasts and subsequent fibrosis. 200X
Bobeck EA(2017) Adenine-induced hyperphosphatemia in a murine model of renal insufficiency
Nephrol Renal Dis, 2017         doi: 10.15761/NRD.1000126  Volume 2(3): 6-7
100% mortality by day 6 when fed 0.75% dietary adenine [14]. Renal 
dysfunction has been shown in mice when fed 0.25% of the diet for 
up to 28 days; however, when we attempted to study 0.25% adenine in 
the diet, we saw profound feed refusal (control=3 g/mouse/day, 0.25% 
adenine≤1 g/mouse/day; unpublished), which presents a problem for 
studying dietary intervention for the control of hyperphosphatemia. 
Studies that have investigated adenine-induced renal dysfunction have 
reported phosphate status in mice; however, serum phosphate was 
not significantly different from control phosphate at all time points 
selected post-induction of dietary adenine, likely due to alternating 
dietary adenine inclusion between 0.15 and 0.20% over a 60 day period 
[15]. Hence we sought to develop an adenine model that minimized 
weight loss possibly due to feed refusal, resulted in low or no mortality, 
effectively induced permanent changes in phosphate status, and did 
not confound feed intake with several dietary additives (i.e., adenine 
plus test compounds to alleviate renal dysfunction). 
In preliminary gavage experiments, 8 or 9 mg adenine/day was 
lethal, while adenine at 1 or 3 mg/day failed to induce increases 
in blood phosphate within a 14-day period (unpublished). In the 
first dosing experiment shown in this paper, we found that altered 
phosphate status (e.g. increased serum phosphate and FGF23) could 
be induced in mice with a 4 mg adenine/day gavage without substantial 
effects on bodyweight loss, and mortality. The increase in serum 
phosphate in mice receiving an adenine gavage was similar to what 
has been reported in studies using rats [8]. Increases in kidney weight 
and serum urea were consistent with renal dysfunction [11,14]. The 
marked increase in blood FGF23 has been previously reported during 
renal failure [8,15,23]. FGF23 is a bone-derived hormone responsible 
for the regulation of blood phosphate homeostasis and is responsible 
for increasing renal excretion of blood phosphate by down regulation 
of the renal sodium-dependent phosphate co-transporter 2a (NaPi2a), 
a transporter responsible for the renal resorption of phosphate. FGF23 
also increases degradation of 1, 25-dihydroxycholecalciferol (active 
vitamin D) and thereby decreases phosphate absorption from the 
intestinal tract via the sodium-dependent phosphate co-transporter 2b 
(NaPi2b) [7]. Hence, elevated levels of serum FGF23 is indicative of a 
mechanism to normalize blood phosphate homeostasis in animals with 
normal renal function.
In the second experiment, we attempted to show that the use of 
calcitriol (1,25-(OH)2 D3) would exacerbate the hyperphosphatemic 
status of renal compromised mice. It is well known that calcitriol 
increases the transport of dietary phosphate in the intestine by 
increasing the number of sodium-dependent phosphate co-transporters 
on the brush border membrane [24]. Patients with CKD are often 
treated with active vitamin D analogs to maintain calcium homeostasis 
and control secondary hyperparathyroidism [25]; however, treatment 
of CKD patients with calcitriol has been shown to increase blood 
phosphate [6]. In the short experimental period shown in this paper, 
daily doses of calcitriol increased serum phosphate at day 7 but not day 
14. Histology revealed that the mice were undergoing a state of vitamin 
D toxicosis (Figure 3H). Elevated FGF23 in mice treated with calcitriol 
was likely successful in controlling blood phosphate levels at day 14 
by increased renal excretion of phosphate and increased degradation 
of calcitriol, and thus decreased absorption of dietary phosphate [22]. 
The reduction in body weight and increased in relative kidney size as 
a result of supplementing adenine-treated mice with calcitriol further 
supports that phosphate metabolism was altered by treating mice with 
calcitriol during renal dysfunction. These findings suggest that the 
mouse adenine model, as described, could be useful in studying the 
adverse affects of calcitriol therapy on phosphate homeostasis.
The primary approach to manage hyperphosphatemia in the CKD 
patient is through oral administration of phosphate binders and dietary 
phosphate reduction [3,26]. Failure to control the hyperphosphatemic 
condition in CKD patients significantly increases the risk of 
cardiovascular disease [27]. Modifying the diet to reduce bioavailable 
phosphate has limited usefulness, but is likely even less effective when 
combined with calcitriol therapy. Calcitriol therapy may increase the 
bioavailablity of phytate phosphate by indirect actions of vitamin D 
[28,29] and direct actions of intestinal alkaline phosphatase [30-32]. 
Hence, the most useful available therapies for the control of blood 
phosphate are oral supplements such as phosphate binders. 
For an animal model of kidney disease to be useful in the study 
of oral therapies for the control of hyperphosphatemia, gut function 
should remain intact. During the gavage studies, it was noted that 
the stomachs were enlarged in mice treated with adenine. While it 
had been previously reported that CKD could alter gastrointestinal 
motility [33], there was no mention in the animal literature of enlarged 
stomachs [8,13,14]. The significant enlargement of the stomach caused 
by adenine supplementation suggested that adenine use in the mouse 
model might compromise oral administration of test therapies. Stomach 
enlargement was not the result of gavage techniques since control mice did 
not experience enlarged stomachs (Figure 2; Tables 2 and 3). 
To determine if the enlarged stomachs associated with adenine 
treatment would impair the study of oral supplements to prevent 
hyperphosphatemia, we studied the interaction of adenine and 
sevelamer. Sevelamer HCl has been shown to be effective at treating 
adenine-induced hyperphosphatemia in rats [8,10], and 5/6 
nephrectomy-induced hyperphosphatemia in mice [34] and rats [35]. 
We have recently demonstrated in chicks that sevelamer HCl was 
effective in preventing the absorption of phosphate liberated from the 
diet due to the treatment of calcitriol [17]. In this report, we found 
that while sevelamer HCl caused a modest reduction in serum FGF23 
after 14 days of supplementation in adenine treated mice, sevelamer 
HCl was ineffective at preventing hyperphosphatemia in this model. 
Sevelamer was supplemented at 1% of the diet, and could potentially bind 
0.45% of the 0.56% dietary phosphate. While sevelamer was not fed in 
excess, the remaining 0.13% phosphate in the diet would have left mice 
severely deficient had sevelamer bound maximal capacity of phosphate. 
It is also likely that sevelamer’s ineffectiveness in this model was 
due to the effect of adenine on gut emptying [36]. The nearly 4-fold 
increase in stomach weight due to adenine treatment appeared to 
be mostly accumulated food. When stomachs were emptied of their 
contents (contents were diet in appearance), the increase in size due to 
adenine use was largely lost. These results suggest that effectiveness 
of sevelamer HCl may have been limited by compromised movement 
through the stomach to reach and bind phosphate in the small intestine 
where phosphate is absorbed. To effectively complex phosphate, 
sevelamer must be in an environment where pH is greater than 5 (such 
as found in the small intestine); sevelamer is unable to bind phosphate 
in the stomach where the pH<4 [37]. Future work should be conducted 
with an increased inclusion of sevelamer (3%) in order to determine 
the contribution of sevelamer dose versus emptying effect on reducing 
hyperphosphatemia.
Conclusion
In conclusion, we have successfully refined a murine adenine 
model of renal dysfunction that can be useful for the study of 
hyperphosphatemia. The model is responsive to calcitriol as would 
be predicted, and histology shows that adenine metabolites are 
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accumulating in kidney tissue and causing mechanical damage, 
inflammation, and reduced filtration. A limitation of the model would 
be the study of dietary modifications or oral supplements that are 
added to the food supply since the use of adenine in the mouse models 
appears to influence stomach emptying.
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